Status:

NOT_YET_RECRUITING

Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study

Lead Sponsor:

Peking Union Medical College Hospital

Conditions:

Aplastic Anemia

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

To investigate the efficacy and safety of roprostin in the treatment of refractory AA after radiotherapy.

Eligibility Criteria

Inclusion

  • Age ≥18 years, male or female.
  • Diagnosis consistent with refractory AA after radiotherapy. refractory is defined as patients who have failed to respond to at least an adequate amount of supportive therapy, cyclosporine or povidone TPO-RA for 3 months .
  • At least one of the following conditions was met at enrolment: haemoglobin \<90 g/L. Platelets \<30 x 10\^9/L, neutrophils \<1.0 x 10\^9/L.
  • Baseline liver and renal function is less than two times the normal value.
  • No active infection.
  • Agreed to sign the consent form.
  • Eastern Cooperative Oncology Group (ECOG) score of 0-2.

Exclusion

  • Other causes of whole blood cytopenia, such as myelodysplastic syndromes (MDS).
  • Presence of cytogenetic evidence of clonal haematological bone marrow disorders (MDS, AML).
  • PNH clones ≥50%.
  • Hematopoietic stem cell transplantation (HSCT) prior to enrolment.
  • Prior treatment with ATG.
  • Infection or bleeding uncontrolled by standard therapy.
  • Allergy to roprostin.
  • Active HIV, HCV or HBV infection or cirrhosis or portal hypertension.
  • Any concomitant malignancy, localised basal cell carcinoma of the skin within 5 years.
  • Previous history of thromboembolic events, heart attack or stroke (including antiphospholipid antibody syndrome) and current use of anticoagulants.
  • Pregnant or lactating (breastfeeding) women.
  • Participation in another clinical trial within 3 months.

Key Trial Info

Start Date :

July 30 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2025

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT06516484

Start Date

July 30 2024

End Date

December 31 2025

Last Update

July 24 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China, 100730